Buybacks
Flow – sum over the period · $M
Q1 FY2023
1,400$M
All values (43)
| Period | Value ($M) | Status |
|---|---|---|
| Q3 FY2026 | 2,232 | derived |
| Q2 FY2026 | 2,111 | derived |
| Q1 FY2026 | 2,478 | reported |
| Q4 FY2025 | 2,474 | derived |
| Q3 FY2025 | 2,057 | derived |
| Q2 FY2025 | 3,500 | derived |
| Q1 FY2025 | 3,250 | reported |
| Q4 FY2024 | 2,500 | derived |
| Q3 FY2024 | 2,500 | derived |
| Q2 FY2024 | 2,500 | derived |
| Q1 FY2024 | 2,000 | reported |
| Q4 FY2023 | 1,000 | derived |
| Q3 FY2023 | 1,000 | derived |
| Q2 FY2023 | 1,000 | derived |
| Q1 FY2023 | 1,400 | reported |
| Q4 FY2022 | 1,750 | derived |
| Q3 FY2022 | 1,200 | derived |
| Q2 FY2022 | 1,200 | derived |
| Q1 FY2022 | 2,400 | reported |
| Q4 FY2021 | 1,000 | derived |
| Q3 FY2021 | 1,000 | derived |
| Q2 FY2021 | 1,000 | derived |
| Q1 FY2021 | 950 | reported |
| Q4 FY2020 | 850 | derived |
| Q3 FY2020 | 500 | derived |
| Q2 FY2020 | 850 | derived |
| Q1 FY2020 | 850 | reported |
| Q4 FY2019 | 750 | derived |
| Q3 FY2019 | 750 | derived |
| Q2 FY2019 | 750 | derived |
| Q1 FY2019 | 500 | reported |
| Q4 FY2018 | 300 | derived |
| Q3 FY2018 | 750 | derived |
| Q2 FY2018 | 700 | derived |
| Q1 FY2018 | 300 | reported |
| Q4 FY2017 | 300 | derived |
| Q3 FY2017 | 300 | derived |
| Q2 FY2017 | 300 | derived |
| Q1 FY2017 | 200 | reported |
| Q4 FY2016 | 300 | derived |
| Q3 FY2016 | 400 | derived |
| Q2 FY2016 | 225 | derived |
| Q1 FY2016 | 150 | reported |
CSV with all sources · Technical ID: buybacks
More metrics for Adobe
Income statement
Balance sheet
Debt and interest
Revenue by segment/product/region
Sources & calculation
- Value
- $1.4B
- Period
- Q1 FY2023, ended Mar 3, 2023 · quarterly value (3 months, not cumulative)
- Source
- 10-Q, filed Mar 29, 2023 · 0000796343-23-000055
- Location
- us-gaap:PaymentsForRepurchaseOfCommonStock
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $1.4B | Mar 29, 2023 | 10-Q 0000796343-23-000055 | reported · confidence 1. · current |